These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 30925542)
1. Comparison of the volumetric and radiomics findings of 18F-FDG PET/CT images with immunohistochemical prognostic factors in local/locally advanced breast cancer. Acar E; Turgut B; Yiğit S; Kaya G Nucl Med Commun; 2019 Jul; 40(7):764-772. PubMed ID: 30925542 [TBL] [Abstract][Full Text] [Related]
2. Association of Önner H; Coskun N; Erol M; Eren Karanis Mİ Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(1):11-16. PubMed ID: 34991831 [TBL] [Abstract][Full Text] [Related]
3. Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031 [TBL] [Abstract][Full Text] [Related]
4. Metabolic Tumor Burden Assessed by Dual Time Point [ Garcia-Vicente AM; Pérez-Beteta J; Pérez-García VM; Molina D; Jiménez-Londoño GA; Soriano-Castrejón A; Martínez-González A Mol Imaging Biol; 2017 Aug; 19(4):636-644. PubMed ID: 27981471 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer. Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372 [TBL] [Abstract][Full Text] [Related]
7. Association of Önner H; Coskun N; Erol M; Karanis MIE Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 Jul; ():. PubMed ID: 34305044 [TBL] [Abstract][Full Text] [Related]
8. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer. García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013 [TBL] [Abstract][Full Text] [Related]
9. Global heterogeneity assessed with Tello Galán MJ; García Vicente AM; Pérez Beteta J; Amo Salas M; Jiménez Londoño GA; Pena Pardo FJ; Soriano Castrejón ÁM; Pérez García VM Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(5):290-297. PubMed ID: 31427247 [TBL] [Abstract][Full Text] [Related]
10. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis. Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034 [TBL] [Abstract][Full Text] [Related]
12. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma. Jung NY; Kim SH; Choi BB; Kim SH; Sung MS World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Kim BS; Sung SH Ann Nucl Med; 2012 Feb; 26(2):175-83. PubMed ID: 22139552 [TBL] [Abstract][Full Text] [Related]
14. Assessment of biological and clinical aggressiveness of invasive ductal breast cancer using baseline 18F-FDG PET/CT-derived volumetric parameters. Ege Aktas G; Taştekin E; Sarikaya A Nucl Med Commun; 2018 Jan; 39(1):83-93. PubMed ID: 29135722 [TBL] [Abstract][Full Text] [Related]
15. Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors. García Vicente AM; Soriano Castrejón A; Cruz Mora MA; González Ageitos A; Muñoz Sánchez Mdel M; León Martín A; Espinosa Aunión R; Relea Calatayud F; Muñoz Madero V; Chacón López-Muñiz I; Cordero García JM; Jiménez Londoño GA Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):72-9. PubMed ID: 23053321 [TBL] [Abstract][Full Text] [Related]
16. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849 [TBL] [Abstract][Full Text] [Related]
17. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer. Kajáry K; Tőkés T; Dank M; Kulka J; Szakáll S; Lengyel Z Nucl Med Commun; 2015 Jan; 36(1):28-37. PubMed ID: 25299471 [TBL] [Abstract][Full Text] [Related]
18. Tumor characteristics and metabolic quantification in carcinoma breast: An institutional experience. Dubey IP; Jain A; Chauhan MS; Kumar R; Agarwal S; Kishore B; Vishnoi MG; Paliwal D; John AR; Kumar N; Sharma A; Pandit AG Indian J Cancer; 2017; 54(1):333-339. PubMed ID: 29199717 [TBL] [Abstract][Full Text] [Related]
19. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG. Wang CL; MacDonald LR; Rogers JV; Aravkin A; Haseley DR; Beatty JD AJR Am J Roentgenol; 2011 Aug; 197(2):W247-55. PubMed ID: 21785049 [TBL] [Abstract][Full Text] [Related]
20. Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]